Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Henry Khederian

Cytokinetics (CYTK) Stock Is Skyrocketing Tuesday: What's Driving The Action?

Shares of Cytokinetics, Inc. (NASDAQ:CYTK) are trading sharply higher Tuesday after the biopharmaceutical company presented new data highlighting the long-term safety and efficacy of its investigational drug, aficamten, at the European Society of Cardiology Congress 2025. Here’s what investors need to know.

What To Know: The company announced several key findings from multiple clinical trials for the cardiac myosin inhibitor, which is being developed to treat hypertrophic cardiomyopathy (HCM), a disease that causes thickening of the heart muscle.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.